Faeth Therapeutics, Inc. - Asset Resilience Ratio
Faeth Therapeutics, Inc. (FTH) has an Asset Resilience Ratio of 84.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Faeth Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Faeth Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See Faeth Therapeutics, Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Faeth Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see FTH current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $159.54 Million | 84.28% |
| Total Liquid Assets | $159.54 Million | 84.28% |
Asset Resilience Insights
- Very High Liquidity: Faeth Therapeutics, Inc. maintains exceptional liquid asset reserves at 84.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Faeth Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Faeth Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Faeth Therapeutics, Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Faeth Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.65% | $12.52 Million | $22.90 Million | -14.44pp |
| 2024-12-31 | 69.09% | $31.34 Million | $45.36 Million | -1.83pp |
| 2023-12-31 | 70.92% | $52.75 Million | $74.37 Million | -4.54pp |
| 2022-12-31 | 75.46% | $89.32 Million | $118.38 Million | -16.21pp |
| 2021-12-31 | 91.67% | $140.46 Million | $153.22 Million | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more